

Exact Therapeutics AS to present at DNB Nordic Healthcare Conference on 16th December 2021

OSLO/LONDON: 13 DECEMBER, 2021: Exact Therapeutics AS (“EXACT-Tx”, or “the Company” Euronext Growth: EXTX), a clinical-stage precision health company evaluating Acoustic Cluster Therapy (ACT®) across multiple therapeutic areas, today announces that its Interim Chief Executive Officer and Chief Financial Officer, Dominic Moreland and Chief Medical Officer, Dr Hilary McElwaine-Johnn will present a corporate overview via live webcast at the DNB [Nordic Healthcare Conference](#) at 3:55pm CET. The Management Team is also available for 1:1 meetings with potential partners and investors.

The presentation will be available at www.exact-tx.com.

DNB is Norway's largest financial services group and one of the largest in the Nordic region in terms of market capitalisation. The Group offers a full range of financial services, including loans, savings, advisory services, insurance and pension products for retail and corporate customers.

END

For more information, please contact:

Dominic Moreland

EXACT Therapeutics

Email: dominic@exact-tx.com

Optimum Strategic Communications

Mary Clark/ Manel Mateus/ Vici Rabbets

Tel: +44 (0) 208 078 0457

Email: Exact@optimumcomms.com

About EXACT

EXACT-Tx is a clinical stage Norwegian biotech company developing a technology platform for targeted therapeutic enhancement – Acoustic Cluster Therapy (ACT®). ACT® follows a unique approach to ultrasound-mediated, targeted drug enhancement – with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy), infectious diseases, and brain diseases. www.exact-tx.com

About ACT®

- ACT® is a proprietary formulation consisting of microbubbles and microdroplets that are activated through the application of ultrasound with the consequent increase in targeted delivery of a co-administered therapeutic agent.
- ACT® is supported by a strong and broad preclinical package demonstrating therapeutic enhancement in multiple oncology models (pancreatic, breast, colon, prostate) as well as blood-brain barrier penetration.
- Initial focus of the Company is in oncology, however the ACT® platform has potential across therapeutic areas (infectious diseases, CNS, immunotherapy) and product classes.